Late-starter sites in randomized controlled trials.

[1]  J. Ioannidis,et al.  Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. , 2001, American journal of epidemiology.

[2]  L. Sjöström,et al.  Principles for Enhanced Recruitment of Subjects in a Large Clinical Trial: The XENDOS Study Experience , 2001 .

[3]  R. Horton,et al.  Sponsorship, authorship, and accountability. , 2001, Obstetrics and gynecology.

[4]  J. Ioannidis,et al.  Patterns of patient enrollment in randomized controlled trials. , 2001, Journal of clinical epidemiology.

[5]  A. Localio,et al.  Adjustments for Center in Multicenter Studies: An Overview , 2001, Annals of Internal Medicine.

[6]  Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies , 2001, BMC medical research methodology.

[7]  H. Chochinov,et al.  Lessons learned from enrollment in the BEST study--a multicenter, randomized trial of group psychosocial support in metastatic breast cancer. , 2000, Journal of clinical epidemiology.

[8]  J. Ioannidis,et al.  Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis. , 1999, Controlled clinical trials.

[9]  J. Young,et al.  Entry into clinical trials in breast cancer: the importance of specialist teams. Scottish Breast Cancer Focus Group and Scottish Cancer Therapy Network. , 1998, European journal of cancer.

[10]  J. Ioannidis.  Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.

[11]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[12]  J Halpern,et al.  Designing a cost-effective clinical trial. , 1995, Statistics in medicine.

[13]  S. Spector,et al.  A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[14]  J. Bartlett,et al.  Performance evaluation in multicenter clinical trials: development of a model by the AIDS Clinical Trials Group. , 1992, Controlled clinical trials.

[15]  J. Fleiss,et al.  Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial (CAST). , 1992, Controlled clinical trials.

[16]  Jeremy MG Taylor,et al.  The Effect of Zidovudine Treatment on Serum Neopterin and β2‐Microglobulin Levels in Mildly Symptomatic, HIV Type 1 Seropositive Individuals , 1992, Journal of acquired immune deficiency syndromes.

[17]  T. Merigan,et al.  Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. , 1991, Blood.

[18]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[19]  A. Detsky,et al.  Are clinical trials a cost-effective investment? , 1989, JAMA.

[20]  J. Schoenberger.  Recruitment experience in the Aspirin Myocardial Infarction Study. , 1987, Controlled clinical trials.

[21]  D. Hunninghake,et al.  Recruitment experience in clinical trials: literature summary and annotated bibliography. , 1987, Controlled clinical trials.

[22]  J. Cutler,et al.  Recruitment of participants for the multiple risk factor intervention trial (MRFIT). , 1987, Controlled clinical trials.

[23]  D. Weiss,et al.  Planning patient recruitment: fantasy and reality. , 1984, Statistics in medicine.

[24]  D. Weiss,et al.  Some adaptive strategies for inadequate sample acquisition in veterans administration cooperative clinical trials. , 1980, Controlled clinical trials.

[25]  T. Prout.  Other examples of recruitment problems and solutions , 1979 .

[26]  J. Schoenberger.  Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study , 1979, Clinical pharmacology and therapeutics.

[27]  LRC Coronary Prevention Trial: Baltimore , 1979, Clinical pharmacology and therapeutics.

[28]  S. Pocock,et al.  Size of cancer clinical trials and stopping rules. , 1978, British Journal of Cancer.